β受体阻滞剂治疗急性冠状动脉综合征疗效观察

Observation on Curative Effect in Treatment of Patients with Acute Coronary Syndrome(ACS) by Beta-receptor Blocker

目的:探讨β受体阻滞剂静脉注射治疗急性冠状动脉综合征(ACS)的效果。方法:总结了2003年3月至2005年3月南煤集团医院收治的86例急性冠状动脉综合征患者,应用倍他乐克治疗的临床资料,对倍他乐克可以降低ACS患者心律失常事件、心肌缺血事件、再梗死率及猝死率进行分析。结果:应用β受体阻滞剂组(A组)死亡率为2.63%,再梗死率为2.63%,AMI为2.63%,未用β受体阻滞剂组(B组)死亡率为8.33%,再梗死率为11.1%,AMI为8.33%,A组的死亡率、再梗死率及AMI发生率均小于B组。结论:在急性冠状动脉综合征中及早静脉注射倍他乐克可以降低心律失常事件、心肌缺血事件、再梗死率及猝死率。

Objective： To investigate the efficacy on intravenous injection of β-receptor blocker in treatment of acute coronary syndrome. Methods： The therapeutic clinical data of Betaloc Used to treat the 86 patients with acute coronary syndrome（ACS） admitted to the Hospital of Nanzhuang Coal Group Ltd. Company between March 2003 and March 2005 were summarized. And the reduction in the incidence of cardiac arrhythmia, myocardial ischemia , reinfarction and sudden death in patients with acute coronary syndrome was analyzed. Results： The death rate of the former group used β-receptor blocker （Group A ） was 2.63%, reinfarction rate was 2.63%, AMI was 2.63%. The death rate in the latter group not used β-receptor blocker （Group B）was 8.33 %, reinfarction rate was 11.1%, AMI was 8.33 %. The death rate, reinfarction rate and the occurrence rate of AMI in group A are smaller than those in group B. Conclusion： The incidence of cardiac arrhythmia, myocardial ischemia, reinfarction and sudden death may be decreased in patients with acute coronary syndrome by early venous injection of Betaloc.